- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01068041
Virkninger af PH3 i diabetisk nefropati (PH3)
The primary objective of this clinical study is to evaluate the effectiveness and safety of PH3 for patients with diabetic nephropathy.
The secondary objectives are to identify the optimal dosage for subsequent studies and to provide basis for the next confirmatory study in study design, endpoints, and study methodologies.
Studieoversigt
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Taichung, Taiwan, 407
- Taichung Veterans General Hospital
-
Taipei, Taiwan
- Taipei Veterans General Hospital
-
Taipei, Taiwan, 114
- Tri-Service General Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Males and Females between 18 and 70 years of age with type 1 or type 2 diabetes
- Sitting blood pressure of <=140/90 mm Hg
- Serum creatinine <=2.0 mg/dL
- Urinary albumin: creatinine ratio between 30 mg/g to 1000 mg/g creatinine (of the first urine sample of the day)
- Hemoglobin A1c <=8%
- Women of child-bearing potential must test negative in a pregnancy test and take contraception measures to prevent pregnancy and can not be breast-feeding
- Voluntary written consent to participate in this study
Exclusion Criteria:
- History of major cardiovascular or cerebrovascular events within 6 months prior to screening
- History of cancer
- Receiving chronic nonsteroidal anti-inflammatory therapy
- History of diabetic ketoacidosis
- Has clinically significant deviation from normal physical examination findings that, in the principal investigator's judgment, may interfere with the study evaluation or affect subject safety
- Has participated in other investigational trials within 28 days prior to study enrollment
- Has taken herbal medical treatment as prescription medication and/or over-the- counter medication, within 28 days prior to study enrollment.
- Has known allergy to the study drug
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: A
Placebo |
Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. |
|
Aktiv komparator: B
250mg active ingredient |
Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. |
|
Aktiv komparator: C
500mg active ingredient |
Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. |
|
Aktiv komparator: D
1000mg active ingredient |
Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Urinary Albumin/Creatinine Ratio (UACR)
Tidsramme: 24 weeks
|
Change in urinary albumin/creatinine ratio (UACR) from baseline to Week 24 |
24 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Urine Albumin
Tidsramme: 24 weeks
|
Change in urine albumin level from baseline to Week 24 |
24 weeks
|
|
Serum Creatinine
Tidsramme: 24 weeks
|
Change in serum creatinine level from baseline to Week 24 |
24 weeks
|
|
Estimated Glomerular Filtration Rate (eGFR)
Tidsramme: 24 weeks
|
Change in estimated glomerular filtration rate (eGFR) from baseline to Week 24 |
24 weeks
|
|
HbA1c
Tidsramme: 24 weeks
|
Change in HbA1c from baseline to Week 24 |
24 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Wu Chang Yang, MD, Taipei Veterans General Hospital, Taiwan
- Ledende efterforsker: Huey-Herng Sheu, MD, PhD, Taichung Veterans General Hospital
- Ledende efterforsker: Yi-Jen Hung, MD, Tri-Service General Hospital (TSGH)
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- PH-CP016
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .